Benson Hill Inc. has reached a significant milestone in its Chapter 11 bankruptcy proceedings. On May 22, 2025, the United States Bankruptcy Court for the District of Delaware approved the sale of substantially all of Benson Hill's assets. The court authorized the Asset Sale to Confluence Genetics, LLC, which includes entities affiliated with S2G Investments, LLC, and ProAgInvest, LLC. This sale was executed under a Bankruptcy Court-approved asset purchase agreement. The agreement encompasses the assumption of certain liabilities and a cash payment to cover closing costs, contractual obligations, and a $1 million wind-down amount. Additionally, the transaction involves the settlement of the $11 million debtor-in-possession credit facility. The approval marks a crucial step in Benson Hill's restructuring process, as the company continues to operate as a debtor-in-possession while pursuing a resolution to its financial challenges.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.